---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-033171"
form_type: "8-K"
ticker: "OTLC"
cik: "0000908259"
company_name: "Oncotelic Therapeutics, Inc."
filed_at: "2026-07-14T20:00:31+00:00"
generated_at: "2026-07-14T20:01:07.738078+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Oncotelic grants 17,796 RSUs to executives tied to exchange uplisting by June 2027

## Summary
- 17,796 RSUs granted to directors, officers, employees, and advisors; each RSU convertible into 1,000 common shares via Series A Preferred.
- CEO Vuong Trieu receives 2,000 RSUs; CMO Anthony Maida and CBO Saran Saund each receive 1,500; CFO Amit Shah receives 1,500.
- RSUs vest only if common stock uplists to a national exchange (e.g., Nasdaq, NYSE) on or before June 30, 2027, plus 6 months service.
- If uplisting does not occur by June 30, 2027, all RSUs expire; change in control accelerates full vesting.
- Potential dilution: up to 17.8 million common shares if all RSUs vest and Preferred converted.

## SEC filing metadata
- accession: 0001493152-26-033171
- form_type: 8-K
- ticker: OTLC
- cik: 0000908259
- company_name: Oncotelic Therapeutics, Inc.
- filed_at: 2026-07-14T20:00:31+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/908259/000149315226033171/0001493152-26-033171-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/908259/000149315226033171/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-033171
- JSON: https://secwatch.observer/filing/0001493152-26-033171.json
- Plain text: https://secwatch.observer/filing/0001493152-26-033171.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.